Genetic and Epigenetic Alterations in Bladder Cancer

Overview

Journal Int Neurourol J

Date 2016 Dec 6

PMID 27915480

Citations 42

Authors

Hong-Tao Li

Christopher E Duymich

Daniel J Weisenberger

Gangning Liang

Affiliations

Soon will be listed here.

Abstract

Bladder cancer is one of the most common cancers worldwide, with a high rate of recurrence and poor outcomes as a result of relapse. Bladder cancer patients require lifelong invasive monitoring and treatment, making bladder cancer one of the most expensive malignancies. Lines of evidence increasingly point to distinct genetic and epigenetic alteration patterns in bladder cancer, even between the different stages and grades of disease. In addition, genetic and epigenetic alterations have been demonstrated to play important roles during bladder tumorigenesis. This review will focus on bladder cancer-associated genomic and epigenomic alterations, which are common in bladder cancer and provide potential diagnostic markers and therapeutic targets for bladder cancer treatment.

Citing Articles

Emerging drivers of female bladder cancer: a pathway to precision prevention and treatment.

Zhang J, Jia H, Han H Front Oncol. 2025; 15:1497637.

PMID: 40027137 PMC: 11867944. DOI: 10.3389/fonc.2025.1497637.

Bladder cancer biomarkers: current approaches and future directions.

Ahangar M, Mahjoubi F, Mowla S Front Oncol. 2024; 14:1453278.

PMID: 39678505 PMC: 11638051. DOI: 10.3389/fonc.2024.1453278.

[High expression of miR-204-5p promotes malignant behaviors of bladder cancer cells by negatively regulating RAB22A].

Li L, Guo Y, Chang R, Sun W, Gao W, Wang C Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(11):2235-2242.

PMID: 39623280 PMC: 11605203. DOI: 10.12122/j.issn.1673-4254.2024.11.21.

Clinicohistopathological Correlation and Prognostic Significance of Molecular Biomarkers in Urinary Bladder Neoplasms: A Comprehensive Analysis.

Mane A, Patil N, Hulwan A, Koley A Cureus. 2024; 16(8):e66088.

PMID: 39229422 PMC: 11368705. DOI: 10.7759/cureus.66088.

Identification of Hydroxysteroid Dehydrogenase Type 1 As a Potential Bladder Tumor Marker.

Albadawy A, Alqudaimi M, Cui H, Yan X, Sun J, Shi P Iran Biomed J. 2024; 28(2&3):120-31.

PMID: 38850011 PMC: 11186615. DOI: 10.61186/ibj.4068.

References

Knowles M, Platt F, Ross R, Hurst C . Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev. 2009; 28(3-4):305-16. PMC: 2797439. DOI: 10.1007/s10555-009-9198-3. View

Jebar A, Hurst C, Tomlinson D, Johnston C, Taylor C, Knowles M . FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005; 24(33):5218-25. DOI: 10.1038/sj.onc.1208705. View

Soussi T, Beroud C . Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2002; 1(3):233-40. DOI: 10.1038/35106009. View

Renard I, Joniau S, Van Cleynenbreugel B, Collette C, Naome C, Vlassenbroeck I . Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol. 2009; 58(1):96-104. DOI: 10.1016/j.eururo.2009.07.041. View

Shtivelman E, Lifshitz B, Gale R, Canaani E . Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985; 315(6020):550-4. DOI: 10.1038/315550a0. View

van Rhijn B, van der Poel H, van der Kwast T . Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 2005; 47(6):736-48. DOI: 10.1016/j.eururo.2005.03.014. View

Williams S, Hurst C, Knowles M . Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2012; 22(4):795-803. PMC: 3554204. DOI: 10.1093/hmg/dds486. View

Liu M, Ohtani H, Zhou W, Orskov A, Charlet J, Zhang Y . Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine. Proc Natl Acad Sci U S A. 2016; 113(37):10238-44. PMC: 5027469. DOI: 10.1073/pnas.1612262113. View

Ghosh M, Brancato S, Agarwal P, Apolo A . Targeted therapies in urothelial carcinoma. Curr Opin Oncol. 2014; 26(3):305-20. PMC: 6777561. DOI: 10.1097/CCO.0000000000000064. View

10.

Duymich C, Charlet J, Yang X, Jones P, Liang G . DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in somatic cells. Nat Commun. 2016; 7:11453. PMC: 4853477. DOI: 10.1038/ncomms11453. View

11.

Han H, Wolff E, Liang G . Epigenetic alterations in bladder cancer and their potential clinical implications. Adv Urol. 2012; 2012:546917. PMC: 3397159. DOI: 10.1155/2012/546917. View

12.

Marsit C, Karagas M, Andrew A, Liu M, Danaee H, Schned A . Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res. 2005; 65(16):7081-5. DOI: 10.1158/0008-5472.CAN-05-0267. View

13.

Simoneau M, Larue H, Aboulkassim T, Meyer F, Moore L, Fradet Y . Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene. 2001; 19(54):6317-23. DOI: 10.1038/sj.onc.1204022. View

14.

Kim E, Kim Y, Jeong P, Ha Y, Bae S, Kim W . Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol. 2008; 180(3):1141-5. DOI: 10.1016/j.juro.2008.05.002. View

15.

Dulic V, Kaufmann W, Wilson S, Tlsty T, Lees E, Harper J . p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 1994; 76(6):1013-23. DOI: 10.1016/0092-8674(94)90379-4. View

16.

He Y, Li B, Li Z, Liu P, Wang Y, Tang Q . Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011; 333(6047):1303-7. PMC: 3462231. DOI: 10.1126/science.1210944. View

17.

Rideout 3rd W, Spruck 3rd C, Hustad C, Coetzee G, Gonzales F, Jones P . Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation. Mol Cell Biol. 1994; 14(9):6143-52. PMC: 359141. DOI: 10.1128/mcb.14.9.6143-6152.1994. View

18.

Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu H . A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res. 2007; 13(24):7296-304. DOI: 10.1158/1078-0432.CCR-07-0861. View

19.

Wu S, Yang Z, Ye R, An D, Li C, Wang Y . Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing. Oncotarget. 2015; 7(3):2629-45. PMC: 4823060. DOI: 10.18632/oncotarget.6380. View

20.

Ding X, Yang X, Liang G, Wang K . Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2'-deoxycytidine. Sci Rep. 2016; 6:24545. PMC: 4835787. DOI: 10.1038/srep24545. View